TOP 3 POSTERS
​Recurrent benign lesion: implications of pain management in dermatology
Bianca N. Eubanks, MD1, Angela M. Crotty, MD2, Aubrey E. Winn, MD3
The Prevalence of Allergens in Best-Selling Mascaras
Samantha Haraszti DO1, Madeline Parson DO1, Anna Figueiredo MD1, Brian Ying2, Jacob Hunter MS2, Juan Jaramillo MBA2, Andrew Racette DO1​
Solitary extramedullary plasmacytoma
Timothy Holland, DO;Angela Crotty, MD; Steven Gauerke, MD; Curtis L Hardy, DO
Atypical Mycobacterium Abscessus Cutaneous Infection in the Immunosuppressed: A Case Report on an Emerging Pathogen
Caden Carver
Analysis of Metformin and Niacin as Skin Cancer Preventative Medications in Solid Organ Transplant Recipients
Courtney Linkous, BA; Nicholas Strat, BS; Chelsea Shope, MSCR; Laura Andrews, MSCR; Lara Wine Lee, MD, PhD
Amoxicillin-Induced DRESS Syndrome with Acute Onset of Diffuse Rash and AKI (Acute Kidney Injury)
Mariane Cortes
Bullous Pyoderma Gangrenosum in a Patient with Anti-phospholipid Syndrome: A Case Report and Literature Review
Mayar Albahrani 
Ustekinumab in hidradenitis suppurativa: a systematic review and meta-analysis 
Rahul Masson 
The approach to the pigmented foot lesion: An advanced case of malignant melanoma and literature review
Whitney Branham
Dupilumab Treatment Normalizes Skin Barrier Composition and Function and Improves Clinical Outcomes in Patients With Atopic Dermatitis
Robert Bissonnette, MD1, Elena Goleva, PhD2, Evgeny Berdyshev, PhD2, Inoncent Agueusop3, Amy Praestgaard, MD4, Noah A. Levit, MD5,
Ana B. Rossi, MD4, Annie Zhang, MD4
Dupilumab: A Comparison of Infection Rates Across Atopic Dermatitis Trials in Adults, Adolescents, Children, and Infants
Peter Lio, MD1, Lisa A. Beck, MD2, Vivian Y. Shi, MD3, Zhen Chen, PhD4, Faisal A. Khokhar, MD4, Sonya L. Cyr, PhD4, Tayler Gonzalez, PharmD5
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial
Jerry Bagel,1 April W Armstrong,2 Richard B Warren,3 Kim A Papp,4 Diamant Thaçi,5 Alan Menter,6 Jennifer Cather,7 Matthias Augustin,8 Lauren Hippeli,9 Carolin Daamen,9 Christopher E M Griffiths3
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of creatine phosphokinase elevations in the phase 3 POETYK PSO-1 and PSO-2 trials
Mark Lebwohl,1 Bruce Strober,2 Thomas Scharnitz,3 Misti Linaberry,3 Kim Hoyt,3 Subhashis Banerjee,3 Renata M Kisa,3 George Martin4
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)
April W Armstrong,1 Mark Lebwohl,2 Jerry Bagel,3 Todd Schlesinger,4 Subhashis Banerjee,5 Renata M Kisa,5 Thomas Scharnitz,5 Kim Hoyt,5 Bruce Strober6
Real-world data demonstrates improved risk stratification by the 31-gene expression profile test for clinical decisions after a negative sentinel lymph node biopsy for patients with melanoma
Brian Martin PhD 1 Christine Bailey, MPH 1 Matthew Goldberg, MD 1 2 Valentina Petkov, MD, MPH 3 Robert Cook, PhD 1 Kyle Covington, PhD 1 Sarah Kurley, PhD 1
Dupilumab Efficacy in Patients With Chronic Spontaneous Urticaria by IgE Level: LIBERTY-CSU CUPID Study A
Marcus Maurer, MD1,2, Thomas B. Casale, MD3, Sarbjit S. Saini, MD4, Moshe Ben-Shoshan, MD5, Allen Radin, MD6, Bola Akinlade, MD6, Elizabeth Laws, PhD7, Leda P. Mannent, MD8
Strategies for Cost Reduction in the Management of Moderate-to-Severe Psoriasis 
Zahab Qazi, BS1; Rohan Singh, BS2; Patrick O. Perche, BS2; Steven R. Feldman, MD, PhD2,3
Improvement in Sleep Quality, Anxiety, and Depression in Adults with Moderate-to-Severe Atopic Dermatitis with Dupilumab Treatment
Joseph F. Merola, MD1, Albert S. Chiou, MD,2 Emmanuel During, MD2, Antonio Costanzo, MD3, Peter Foley, MD4, Marius Ardeleanu, MD5, Jiangming Wu, PhD6, Zafer E. Ozturk, MD7
Efficacy of spesolimab for Generalized Pustular Psoriasis (GPP) flare treatment according to GPP Area and Severity Index (GPPASI) score at baseline
Melinda Gooderham1, Shinichi Imafuku2, Ricardo Romiti3, Dagmar Wilsmann-Theis4, Min Zheng5, Ling Li6, Manuel Quaresma7, Christian Thoma8, Mark G. Lebwohl9
Sustained treatment effect of spesolimab over 12 weeks for generalized pustular psoriasis flares: Results from the Effisayil 1 study
Boni Elewski1, Jonathan Barker2, Ulrich Mrowietz3, Shinichi Imafuku4, Jinhua Xu5, Na Hu6, Manuel Quaresma7, Christian Thoma8, Hervé Bachelez9,10
Education on Transgender Medicine During Dermatology Residency
Adrija Darsha BS1*, Tiffany Loh MD2*, Arisa Ortiz MD3*
Prediction of Quality of Life using the Optimal Psoriasis Assessment Tool (OPAT™) in Real-World Ixekizumab Patients
Craig L. Leonardi,1Benjamin Lockshin,2William Malatestinic,3Baojin Zhu,3 Meghan Feely,3,4Julie McCormack,5Miriam Kimel,5 Yunyang Zhao,3 Kyoungah See,3Russel Burge3
Assessment of Serial Staged Punch Excision (SSPE) as a Novel Technique for Epidermal Nevus and Nevus Sebaceous Removal
M. G. Buethe, MD, PhD, K. M. Derrick, MD, S. A. Glick, MD, F. Asrani, MD.
Efficacy and Safety of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis From the JADE Clinical Trial Program
Lawrence F. Eichenfield,1 Carsten Flohr,2 Christine Bangert,3 Alan D. Irvine,4 Stephan Weidinger,5John Nesnas,6 Herwig Koppensteiner,7 Fan Zhang,8a Ricardo Rojo,8a Gary Chan8
Abrocitinib Safety in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years
Eric L. Simpson,1 Jonathan I. Silverberg,2 Audrey Nosbaum,3 Kevin Winthrop,1 Emma Guttman-Yassky,4 Karin M. Hoffmeister,5 Alexander Egeberg,6 Hernan Valdez,7a Haiyun Fan,8 Saleem A. Farooqui,9 Gary Chan,10 Justine Alderfer,8 William Romero,11 Susan Johnson12
Regional differences in telehealth access for patients with inflammatory skin conditions in the United States
Edwin Korouri, BS1; Paige Kingston, BS2; Hannah Peterson, BS3; Danielle Yee, MD2; Margaret Y. Huang, BS2; Kathryn Lee, BA4; Rosario Agüero, MD2; April W. Armstrong, MD, MPH2
Prevalence of Pruritus with Use of Metformin and Other Oral Hypoglycemic Agents
L. Sattele, BS1; C. Linkous, BA1,2; L. Andrews, MSCR2; C. Shope, MSCR2; N. Strat, BS1; L. Wine Lee, MD, PhD3
Is there a clinically relevant risk of hyperkalemia with topical clascoterone treatment?
James Del Rosso1, Linda Stein Gold2, Nicholas Squittieri3, Diane Thiboutot4
Long-term safety and efficacy of 1% clascoterone cream in patients ≥12 years old with acne vulgaris
Lawrence F Eichenfield1, Adelaide A Hebert2, Linda Stein Gold3, Martina Cartwright4, Luigi Moro5, Jenny Han6, Nicholas Squittieri7, Alessandro Mazzetti5
Patients’ quality of life and satisfaction with treatment in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis
Jayme Heim1, J Gabriel Vasquez1, Ranga Gogineni2, Brad Schenkel2, Neal Bhatia3
The efficacy and safety of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light for the treatment of facial cutaneous squamous cell carcinoma in situ
Mark S Nestor1–3, Haowei Han1, Faraz Yousefian1, Ciaran Smythe1
Patient-reported symptom relief in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis
J Gabriel Vasquez1, Neal Bhatia2, Brad Schenkel3, Ranga Gogineni3, Jayme Heim1
Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodularis: Pooled Results From Two Phase 3 Trials (LIBERTY-PN PRIME and PRIME2)
Gil Yosipovitch, MD1, Shawn G. Kwatra, MD2, Nicholas Mollanazar, MD3, Sonja Ständer, MD4, Takahiro Satoh, PhD5, Elizabeth Laws, PhD6, Leda P. Mannent, MD7, Eric Mortensen, MD8, Jennifer Maloney, MD8, Genming Shi, PhD6, Ashish Bansal, MD8, Renata Martinˇcová, MD9